IN2012DN05175A - - Google Patents

Download PDF

Info

Publication number: IN2012DN05175A
Authority: IN; India
Prior art keywords: antibodies; binding regions; antigen; disorders; cancer
Prior art date: 2009-12-09

Application number

Other languages

English (en)

Inventor

Linden Lars

Cao Yong-Jiang

Leder Gabriele

Stelte-Ludwig Beatrix

Harrenga Axel

Finnern Ricarda

Dittmer Frank

Mayer-Bartschmid Anke

Franz Juergen

Greven Simone

Willuda Jorg

Tebbe Jan

Original Assignee

Bayer Pharma AG

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-12-09

Filing date

2010-12-08

Publication date

2015-10-23

2010-12-08 Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG

2015-10-23 Publication of IN2012DN05175A publication Critical patent/IN2012DN05175A/en

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
- A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
General Health & Medical Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Cell Biology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Oncology (AREA)
Microbiology (AREA)
Mycology (AREA)
General Chemical & Material Sciences (AREA)
Toxicology (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Radiology & Medical Imaging (AREA)
Inorganic Chemistry (AREA)
Biotechnology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

IN5175DEN2012 2009-12-09 2010-12-08 IN2012DN05175A (ru)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP09178474		2009-12-09
EP10170797		2010-07-26
PCT/EP2010/069216 WO2011070088A1 (en)	2009-12-09	2010-12-08	Anti-c4.4a antibodies and uses thereof

Publications (1)

Publication Number	Publication Date
IN2012DN05175A true IN2012DN05175A (ru)	2015-10-23

Family

ID=43629588

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IN5175DEN2012 IN2012DN05175A (ru)	2009-12-09	2010-12-08

Country Status (27)

Country	Link
US (2)	US20120321619A1 (ru)
EP (2)	EP3144323A3 (ru)
JP (3)	JP5989544B2 (ru)
KR (1)	KR101931820B1 (ru)
CN (1)	CN102812047B (ru)
AR (1)	AR079340A1 (ru)
AU (1)	AU2010329904B2 (ru)
BR (1)	BR112012013915A8 (ru)
CA (1)	CA2783338A1 (ru)
CY (1)	CY1119051T1 (ru)
DK (1)	DK2510012T3 (ru)
ES (1)	ES2632748T3 (ru)
HR (1)	HRP20170973T1 (ru)
HU (1)	HUE034847T2 (ru)
IL (1)	IL219801A (ru)
IN (1)	IN2012DN05175A (ru)
LT (1)	LT2510012T (ru)
MX (1)	MX2012006593A (ru)
NZ (1)	NZ600470A (ru)
PL (1)	PL2510012T3 (ru)
PT (1)	PT2510012T (ru)
RS (1)	RS56161B1 (ru)
RU (1)	RU2577977C2 (ru)
SI (1)	SI2510012T1 (ru)
TW (1)	TWI488642B (ru)
WO (1)	WO2011070088A1 (ru)
ZA (1)	ZA201203498B (ru)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP5881604B2 (ja) *	2010-06-15	2016-03-09	国立大学法人大阪大学	癌予後判定可能な抗体、および癌予後判定方法
EP3501546A3 (de) *	2011-04-21	2019-09-18	Seattle Genetics, Inc.	Cystein-wirkstoff konjugate und ihre verwendung
JP2014117191A (ja) *	2012-12-13	2014-06-30	Fisheries Research Agency	リン酸化中性スフィンゴミエリナーゼ１、抗リン酸化中性スフィンゴミエリナーゼ１抗体、中性スフィンゴミエリナーゼ１変異体、及びそれらの用途
CN107074940A (zh) *	2014-09-09	2017-08-18	德州大学系统董事会	针对agr2和其受体c4.4a的阻断性单克隆抗体
EP3283522A1 (en)	2015-04-17	2018-02-21	Spring Bioscience Corporation	Antibodies, compositions, and immunohistochemistry methods for detecting c4.4a
EP3383497A4 (en) *	2015-12-04	2019-06-12	The Regents of The University of California	NOVEL ANTIBODIES FOR THE TREATMENT OF CANCER DISEASES
WO2017156280A1 (en) *	2016-03-09	2017-09-14	Viba Therapeutics, Inc.	Methods of treating cancer using monoclonal antibodies to agr2 and c4.4a
EP3568158A4 (en)	2017-01-11	2020-11-18	The Board of Trustees of the Leland Stanford Junior University	R-SPONDIN SUBSTITUTION MOLECULES (RSPO)
WO2018140821A1 (en)	2017-01-26	2018-08-02	Surrozen, Inc.	Tissue-specific wnt signal enhancing molecules and uses thereof
JP7052389B2 (ja) *	2018-02-07	2022-04-12	株式会社三洋物産	遊技機
EP3820499A4 (en)	2018-07-09	2022-07-13	Surrozen Operating, Inc.	TISSUE SPECIFIC WNT SIGNAL ENHANCEMENT MOLECULES AND USES
US20210309711A1 (en) *	2018-07-20	2021-10-07	Duke University	Anti-lypd3 car t-cell therapy for the treatment of cancer
CN113015810B (zh) *	2018-11-08	2024-07-05	国立大学法人香川大学	含有稀少糖的组合物的制造方法和含有稀少糖的组合物
CN111349164B (zh) *	2018-12-21	2023-05-26	艾比玛特医药科技（上海）有限公司	糖基磷脂酰肌醇锚定糖蛋白（c4.4a）的单克隆抗体及其应用
WO2020257770A1 (en) *	2019-06-21	2020-12-24	Children's National Medical Center	Methods and composition for a binding molecule targeting cancer cells expressing ssx2 peptide 41-49 in hla-a*0201 context
AR120430A1 (es)	2019-11-08	2022-02-16	Humanigen Inc	Células car-t dirigidas a epha3 para el tratamiento de tumores
CA3198268A1 (en)	2020-11-16	2022-05-19	Surrozen Operating, Inc.	Liver-specific wnt signal enhancing molecules and uses thereof
IL315431A (en)	2022-03-16	2024-11-01	Pentixapharm Ag	Antibodies against lypd3
WO2023240135A2 (en)	2022-06-07	2023-12-14	Actinium Pharmaceuticals, Inc.	Bifunctional chelators and conjugates

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4657760A (en)	1979-03-20	1987-04-14	Ortho Pharmaceutical Corporation	Methods and compositions using monoclonal antibody to human T cells
US4634665A (en)	1980-02-25	1987-01-06	The Trustees Of Columbia University In The City Of New York	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en)	1980-02-25	1983-08-16	The Trustees Of Columbia University	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en)	1980-02-25	1993-01-12	The Trustees Of Columbia University In The City Of New York	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en)	1982-11-18	1985-04-09	Chiron Corporation	Adenovirus promoter system
GB8308235D0 (en)	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
US5168062A (en)	1985-01-30	1992-12-01	University Of Iowa Research Foundation	Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5206344A (en)	1985-06-26	1993-04-27	Cetus Oncology Corporation	Interleukin-2 muteins and polymer conjugation thereof
US4968615A (en)	1985-12-18	1990-11-06	Ciba-Geigy Corporation	Deoxyribonucleic acid segment from a virus
IL85035A0 (en)	1987-01-08	1988-06-30	Int Genetic Eng	Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5225212A (en)	1989-10-20	1993-07-06	Liposome Technology, Inc.	Microreservoir liposome composition and method
ATE255131T1 (de)	1991-06-14	2003-12-15	Genentech Inc	Humanisierter heregulin antikörper
ATE219517T1 (de)	1995-08-18	2002-07-15	Morphosys Ag	Protein-/(poly)peptidbibliotheken
JP4318752B2 (ja) *	1996-05-31	2009-08-26	ヘルス・リサーチ・インコーポレーテッド	抗エンドグリンモノクローナル抗体および抗血管新生治療におけるその使用
US6194551B1 (en)	1998-04-02	2001-02-27	Genentech, Inc.	Polypeptide variants
IL138608A0 (en)	1998-04-02	2001-10-31	Genentech Inc	Antibody variants and fragments thereof
US6737056B1 (en)	1999-01-15	2004-05-18	Genentech, Inc.	Polypeptide variants with altered effector function
WO2001023553A2 (en) *	1999-09-29	2001-04-05	Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts	Metastasis-associated antigen c4.4a
CA2450793A1 (en) *	2001-06-20	2002-12-27	Prochon Biotech Ltd.	Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
MXPA06014065A (es) *	2004-06-01	2007-01-31	Genentech Inc	Conjugados de droga-anticuerpo y metodos.
JP2010512324A (ja) *	2006-12-08	2010-04-22	アッテヌオンエルエルシー	ウロキナーゼ型プラスミノーゲン活性化因子受容体エピトープ、それに由来するモノクローナル抗体及びそれらの使用方法
EP3501546A3 (de) *	2011-04-21	2019-09-18	Seattle Genetics, Inc.	Cystein-wirkstoff konjugate und ihre verwendung

2010
- 2010-12-08 RS RS20170650A patent/RS56161B1/sr unknown
- 2010-12-08 JP JP2012542543A patent/JP5989544B2/ja not_active Expired - Fee Related
- 2010-12-08 CA CA2783338A patent/CA2783338A1/en not_active Abandoned
- 2010-12-08 SI SI201031493T patent/SI2510012T1/sl unknown
- 2010-12-08 WO PCT/EP2010/069216 patent/WO2011070088A1/en not_active Ceased
- 2010-12-08 US US13/514,789 patent/US20120321619A1/en not_active Abandoned
- 2010-12-08 ES ES10798996.4T patent/ES2632748T3/es active Active
- 2010-12-08 EP EP16191498.1A patent/EP3144323A3/en not_active Withdrawn
- 2010-12-08 HR HRP20170973TT patent/HRP20170973T1/hr unknown
- 2010-12-08 BR BR112012013915A patent/BR112012013915A8/pt not_active Application Discontinuation
- 2010-12-08 MX MX2012006593A patent/MX2012006593A/es active IP Right Grant
- 2010-12-08 AU AU2010329904A patent/AU2010329904B2/en not_active Ceased
- 2010-12-08 PT PT107989964T patent/PT2510012T/pt unknown
- 2010-12-08 NZ NZ600470A patent/NZ600470A/en not_active IP Right Cessation
- 2010-12-08 EP EP10798996.4A patent/EP2510012B1/en active Active
- 2010-12-08 PL PL10798996T patent/PL2510012T3/pl unknown
- 2010-12-08 CN CN201080063444.XA patent/CN102812047B/zh not_active Expired - Fee Related
- 2010-12-08 IN IN5175DEN2012 patent/IN2012DN05175A/en unknown
- 2010-12-08 DK DK10798996.4T patent/DK2510012T3/en active
- 2010-12-08 KR KR1020127017608A patent/KR101931820B1/ko not_active Expired - Fee Related
- 2010-12-08 TW TW099142735A patent/TWI488642B/zh not_active IP Right Cessation
- 2010-12-08 LT LTEP10798996.4T patent/LT2510012T/lt unknown
- 2010-12-08 HU HUE10798996A patent/HUE034847T2/en unknown
- 2010-12-08 RU RU2012128343/10A patent/RU2577977C2/ru not_active IP Right Cessation
- 2010-12-09 AR ARP100104549A patent/AR079340A1/es unknown
2012
- 2012-05-14 ZA ZA2012/03498A patent/ZA201203498B/en unknown
- 2012-05-15 IL IL219801A patent/IL219801A/en not_active IP Right Cessation
2016
- 2016-03-03 JP JP2016040961A patent/JP6240696B2/ja not_active Expired - Fee Related
2017
- 2017-02-06 US US15/425,397 patent/US20170158775A1/en not_active Abandoned
- 2017-07-04 CY CY20171100712T patent/CY1119051T1/el unknown
- 2017-11-02 JP JP2017212592A patent/JP2018019721A/ja active Pending

Also Published As

Publication number	Publication date
WO2011070088A1 (en)	2011-06-16
PT2510012T (pt)	2017-07-13
TWI488642B (zh)	2015-06-21
TW201134485A (en)	2011-10-16
EP2510012B1 (en)	2017-04-19
SI2510012T1 (sl)	2017-08-31
RU2577977C2 (ru)	2016-03-20
JP2016104820A (ja)	2016-06-09
CN102812047B (zh)	2015-08-26
CN102812047A (zh)	2012-12-05
JP5989544B2 (ja)	2016-09-07
KR20120116958A (ko)	2012-10-23
ZA201203498B (en)	2015-10-28
HUE034847T2 (en)	2018-03-28
AU2010329904B2 (en)	2015-07-09
JP2018019721A (ja)	2018-02-08
PL2510012T3 (pl)	2017-09-29
NZ600470A (en)	2015-02-27
US20120321619A1 (en)	2012-12-20
JP2013513369A (ja)	2013-04-22
BR112012013915A8 (pt)	2017-12-26
US20170158775A1 (en)	2017-06-08
MX2012006593A (es)	2012-06-28
RU2012128343A (ru)	2014-01-20
CY1119051T1 (el)	2018-01-10
DK2510012T3 (en)	2017-07-31
HK1178920A1 (en)	2013-09-19
IL219801A0 (en)	2012-07-31
AU2010329904A1 (en)	2012-06-14
KR101931820B1 (ko)	2018-12-21
RS56161B1 (sr)	2017-11-30
IL219801A (en)	2016-08-31
CA2783338A1 (en)	2011-06-16
EP3144323A3 (en)	2017-05-31
HRP20170973T1 (hr)	2017-09-22
LT2510012T (lt)	2017-07-25
EP3144323A2 (en)	2017-03-22
BR112012013915A2 (pt)	2017-01-10
AR079340A1 (es)	2012-01-18
ES2632748T3 (es)	2017-09-15
EP2510012A1 (en)	2012-10-17
JP6240696B2 (ja)	2017-11-29

Publication	Publication Date	Title
TN2010000234A1 (en)	2011-11-11	Anti-mesothelin antibodies and uses therefor
EP3144323A3 (en)	2017-05-31	Anti-c4.4a antibodies and uses thereof
MX2015016814A (es)	2016-08-08	Anticuerpo anti-tweakr y sus usos.
SG142330A1 (en)	2008-05-28	Anti-cd38 human antibodies and uses therefor
MX2024015844A (es)	2025-02-10	Anticuerpos agonistas que se unen a cd137 humano y sus usos
EA202092735A1 (ru)	2021-04-22	Антагонизирующее cd73 антитело
EA202091710A1 (ru)	2021-02-16	Антитела против cd73 и способы их применения
EA201891366A1 (ru)	2018-12-28	Гуманизированные антитела против cd73
MX2019013172A (es)	2020-09-07	Composiciones y metodos para tratar la enfermedad de huntington.
PH12018500694A1 (en)	2018-10-01	Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins
MA44885B1 (fr)	2026-02-27	Protéines de liaison bispécifiques et leurs utilisations
EA202090956A2 (ru)	2020-09-30	Антитела к cd73 и их применения
MY197322A (en)	2023-06-13	Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
EA201790799A1 (ru)	2017-08-31	Композиции и способы для применения для усиления иммунного ответа и терапии злокачественных опухолей
PL422231A1 (pl)	2018-01-29	Komórki immunologiczne CAR do leczenia nowotworów
UA106492C2 (ru)	2014-09-10	Иммуноконьюгаты анти-мезотелина, их получение и применение
PH12017500331A1 (en)	2017-07-17	Antigen binding proteins that bind cxcr5
MX2010010387A (es)	2010-10-15	Anticuerpos especificos para el complejo de bcr y metodos para el uso de los mismos.
WO2015108998A3 (en)	2015-10-22	Cartilage targeting agents and their use
UA115540C2 (uk)	2017-11-27	Антитіло до il-36r
PH12013500990A1 (en)	2022-11-23	Neutralizing anti-ccl20 antibodies
TN2018000159A1 (en)	2019-10-04	Improved tnf binders.
WO2014151982A3 (en)	2015-01-08	Arginine deiminase with reduced cross-reactivity toward adi – peg 20 antibodies for cancer treatment
CA2949045A1 (en)	2015-06-25	Alpha-enolase specific antibodies and methods of uses in cancer therapy
MX2011008456A (es)	2011-09-26	Anticuerpos anti-mst1r y usos de los mismos.